- Home
- WENC vs PLX Comparison
WENC vs PLX Comparison
Compare WENC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.55
Company Overview
Basic Information| Metric | WENC | PLX |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 207.1M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WENC | PLX |
|---|---|---|
| Price | $10.02 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.4K | ★ 840.6K |
| Earning Date | N/A | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.06 | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $166.92 | ★ $9.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.89 | $1.65 |
| 52 Week High | $10.05 | $3.19 |
Technical Indicators
Market Signals| Indicator | WENC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 42.21 |
| Support Level | $9.99 | $2.21 |
| Resistance Level | N/A | $2.75 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 41.67 | 7.41 |
Price Performance
Historical Comparison WENC
PLX
About WENC West Enclave Merger Corp. Ordinary Shares
West Enclave Merger Corp is a blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.